Study of AT-527 in Healthy and HCV-Infected Subjects

Inclusion Criteria

• •All subjects (healthy and HCV-infected subjects):
• •Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
• •Must have a negative pregnancy test at Screening and prior to dosing
• •Minimum body weight of 50 kg
• •Willing to comply with the study requirements and to provide written informed consent
• •Must have not received prior treatment for HCV infection
• •Documented clinical history compatible with chronic HCV infection
• •Plasma HCV RNA ≥ 5.0 log10 IU/mL at Screening.